# Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer

> **NCT02267603** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 50 (actual)

## Conditions studied

- Recurrent Merkel Cell Carcinoma
- Stage III Merkel Cell Carcinoma AJCC v7
- Stage IIIA Merkel Cell Carcinoma AJCC v7
- Stage IIIB Merkel Cell Carcinoma AJCC v7
- Stage IV Merkel Cell Carcinoma AJCC v7

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02267603
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-25
- **Primary completion:** 2018-02-06
- **Final completion:** 2021-12-15
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2023-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02267603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02267603, "Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02267603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*